1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin 2018, 68:7e30
2. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo CC, Lotan Y, Kassouf W: Bladder cancer. Lancet 2016, 388:2796e2810
3. Knowles MA, Hurst CD: Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015, 15:25e41
4. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507: 315e322
5. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ: Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25:152e165
6. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY: Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014, 111: 3110e3115
7. Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Neuzillet Y, Denoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F: EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014, 6:244ra91
8. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al: Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017, 171:540e556.e25
9. Marzouka NA, Eriksson P, Rovira C, Liedberg F, Sjodahl G, Hoglund M: A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep 2018, 8:3737
10. Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K, Xiao J, Shen J, Chan KS: Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst 2018, 110:448e459
11. Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP: Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol 2019, 75:423e432
12. Black PC, Brown GA, Dinney CP: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009, 27:3e7
13. Minato A, Fujimoto N, Kubo T: Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder. Clin Geni- tourin Cancer 2017, 15:e1063ee1067
14. Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C: Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer 2015, 15:42e54
15. Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, Stewart KG, Chai S, Manocha U, Byrd KM, Damrauer JS, Williams SE, Vincent BG, Kim WY: Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res 2018, 78:3954e3968
16. Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Sze CC, Wang L, Zhao Z, Crawford SE, Hu D, Licht JD, Collings CK, Bartom E, Theodorescu D, Shilatifard A, Meeks JJ: A carcinogen- induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene 2018, 37: 1911e1925
17. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C, Abate-Shen C: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009, 23:675e680
18. Owczarek TB, Kobayashi T, Ramirez R, Rong L, Puzio-Kuter AM, Iyer G, Teo MY, Sanchez-Vega F, Wang J, Schultz N, Zheng T, Solit DB, Al-Ahmadie HA, Abate-Shen C: ARF confers a context-dependent response to chemotherapy in muscle-invasive bladder cancer. Cancer Res 2017, 77:1035e1046
19. Nishizawa K, Nishiyama H, Matsui Y, Kobayashi T, Saito R, Kotani H, Masutani H, Oishi S, Toda Y, Fujii N, Yodoi J, Ogawa O: Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis 2011, 32:1459e1466
20. Vasconcelos-Nobrega C, Colaco A, Lopes C, Oliveira PA: Review: BBN as an urothelial carcinogen. In Vivo 2012, 26:727e739
21. Shin K, Lim A, Zhao C, Sahoo D, Pan Y, Spiekerkoetter E, Liao JC, Beachy PA: Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 2014, 26:521e533
22. Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, Schneider K, Oyon D, Dunlop M, Wu XR, Cordon- Cardo C, Mendelsohn C: Bladder cancers arise from distinct uro- thelial sub-populations. Nat Cell Biol 2014, 16:982e991. 1-5
23. Tarutani M, Itami S, Okabe M, Ikawa M, Tezuka T, Yoshikawa K, Kinoshita T, Takeda J: Tissue-specific knockout of the mouse Pig-a gene reveals important roles for GPI-anchored proteins in skin development. Proc Natl Acad Sci U S A 1997, 94:7400e7405
24. Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ: Faithful activation of an extra-bright red fluorescent protein in “knock-in” Cre-reporter mice ideally suited for lineage tracing studies. Eur J Immunol 2007, 37:43e53
25. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T: Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847e860
26. Shen TH, Gladoun N, Castillo-Martin M, Bonal D, Domingo- Domenech J, Charytonowicz D, Cordon-Cardo C: A BAC-based transgenic mouse specifically expresses an inducible Cre in the uro- thelium. PLoS One 2012, 7:e35243
27. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibi- tor. Clin Cancer Res 2000, 6:2053e2063
28. Liu L, Ye TH, Han YP, Song H, Zhang YK, Xia Y, Wang NY, Xiong Y, Song XJ, Zhu YX, Li de L, Zeng J, Ran K, Peng CT, Wei YQ, Yu LT: Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem 2014, 33:633e645
29. Seager C, Puzio-Kuter AM, Cordon-Cardo C, McKiernan J, Abate- Shen C: Mouse models of human bladder cancer as a tool for drug discovery. Curr Protoc Pharmacol 2010. Chapter 14:Unit 14
30. R Development Core Team: R, A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2009
31. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43:e47
32. Bult CJ, Blake JA, Smith CL, Kadin JA, Richardson JE; Mouse Genome Database Group: Mouse genome database (MGD) 2019. Nucleic Acids Res 2019, 47:D801eD806
33. Jain AK, Dubes RC: Algorithms for Clustering Data. Englewood Cliffs, NJ, Prentice Hall Inc., 1988
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545e15550
35. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267e273
36. Saito R, Shirakawa R, Nishiyama H, Kobayashi T, Kawato M, Kanno T, Nishizawa K, Matsui Y, Ohbayashi T, Horiguchi M, Nakamura T, Ikeda T, Yamane K, Nakayama E, Nakamura E, Toda Y, Kimura T, Kita T, Ogawa O, Horiuchi H: Downregulation of Ral GTPase-activating protein promotes tumor invasion and metas- tasis of bladder cancer. Oncogene 2013, 32:894e902
37. Warrick JI, Walter V, Yamashita H, Chung E, Shuman L, Amponsa VO, Zheng Z, Chan W, Whitcomb TL, Yue F, Iyyanki T, Kawasawa YI, Kaag M, Guo W, Raman JD, Park JS, DeGraff DJ: FOXA1, GATA3 and PPAR cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines. Sci Rep 2016, 6:38531
38. Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjot L, Hoglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Tax- onomy Group: A consensus molecular classification of muscle- invasive bladder cancer. Eur Urol 2020, 77:420e433
39. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjodahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhofer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall’Era M, van der Heijden MS, Black PC: Impact of molecular subtypes in muscle- invasive bladder cancer on predicting response and survival after neo- adjuvant chemotherapy. Eur Urol 2017, 72:544e554
40. Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall’Era M, van der Heijden MS, Wright JL, Black PC: Divergent biological response to neoadjuvant chemo- therapy in muscle-invasive bladder cancer. Clin Cancer Res 2019, 25:5082e5093
41. Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ: Pre- dictive biomarkers for drug response in bladder cancer. Int J Urol 2019, 26:1044e1053
42. Nickerson ML, Witte N, Im KM, Turan S, Owens C, Misner K, Tsang SX, Cai Z, Wu S, Dean M, Costello JC, Theodorescu D: Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene 2017, 36:35e46
43. Gandhi D, Molotkov A, Batourina E, Schneider K, Dan H, Reiley M, Laufer E, Metzger D, Liang F, Liao Y, Sun TT, Aronow B, Rosen R, Mauney J, Adam R, Rosselot C, Van Batavia J, McMahon A, McMahon J, Guo JJ, Mendelsohn C: Retinoid signaling in pro- genitors controls specification and regeneration of the urothelium. Dev Cell 2013, 26:469e482
44. He X, Marchionni L, Hansel DE, Yu W, Sood A, Yang J, Parmigiani G, Matsui W, Berman DM: Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 2009, 27:1487e1495
45. Warrick JI, Sjodahl G, Kaag M, Raman JD, Merrill S, Shuman L, Chen G, Walter V, DeGraff DJ: Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol 2019, 75:18e22